Sotorasib in KRASG12C mutated lung cance Reply

被引：0
|
作者：
Paz-Ares, Luis [1 ]
Mehta, Bhakti [3 ]
Wang, Yang [3 ]
Obiozor, Cynthia [3 ]
Waterhouse, David [2 ]
de Langen, Adrianus Johannes [4 ]
机构：
[1] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid 28041, Spain
[2] Oncol Hematol Care, Cincinnati, OH USA
[3] Amgen Inc, Thousand Oaks, CA USA
[4] Netherlands Canc Inst, Amsterdam, Netherlands
来源：
LANCET | 2024年 / 403卷 / 10422期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：145 / 146
页数：2
相关论文
共 50 条
  • [31] SHERLOCK: Phase II Trial of Upfront Sotorasib with Chemotherapy and Bevacizumab for Advanced NSCLC with KRASG12C Mutation
    Lee, C.
    Pavlakis, N.
    Zhou, D. D. -X.
    Brown, C.
    Hughes, B. G. M.
    Yip, S.
    Bray, V. J.
    Daley, F. T.
    Roberts-Thomson, R.
    Cummins, M. M.
    John, T.
    Solomon, B. J.
    Mitchell, P.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S361 - S362
  • [32] RMC-6291, a next-generation tri-complex KRASG12C(ON) inhibitor, outperforms KRASG12C(OFF) inhibitors in preclinical models of KRASG12C cancers
    Nichols, Robert J.
    Yang, Y. C.
    Cregg, Jim
    Schulze, Chris J.
    Wang, Zhican
    Dua, Richa
    Jiang, Jingjing
    Garrenton, Lindsay S.
    Nasholm, Nicole
    Bermingham, Alun
    Knox, John E.
    Seamon, Kyle
    Longhi, Michael
    Chou, Kang-Jye
    Li, Shaoling
    Wildes, David P.
    Singh, Mallika
    Koltun, Elena S.
    Gill, Adrian L.
    Smith, Jacqueline A. M.
    CANCER RESEARCH, 2022, 82 (12)
  • [33] Proteomic and transcriptomic subtypes of KRASG12c mutant lung cancer.
    Solanki, Hitendra Singh
    Stewart, Paul A.
    Welsh, Eric A.
    Izumi, Victoria
    Fang, Bin
    Yoder, Sean J.
    Koomen, John M.
    Haura, Eric B.
    CANCER RESEARCH, 2022, 82 (12)
  • [34] Resistance looms for KRASG12C inhibitors
    Hata, Aaron N.
    Shaw, Alice T.
    NATURE MEDICINE, 2020, 26 (02) : 169 - 170
  • [35] KRASG12C inhibition in tumor therapy
    Alakus, Hakan
    Hartmann, Milan
    Ast, David
    Bruns, Christiane
    ONKOLOGE, 2021, 27 (01): : 72 - 73
  • [36] Mechanisms of Resistance to KRASG12C Inhibitors
    Dunnett-Kane, Victoria
    Nicola, Pantelis
    Blackhall, Fiona
    Lindsay, Colin
    CANCERS, 2021, 13 (01) : 1 - 14
  • [37] Trials, Tribunals, and Opportunities for Lung Cancer KRASG12C Brain Metastases
    Kommalapati, Anuhya
    Mansfield, Aaron S.
    CLINICAL CANCER RESEARCH, 2022, 28 (15) : 3179 - 3181
  • [38] Remarkable Intracranial Response to Sotorasib in a Patient With KRASG12C-Mutated Lung Adenocarcinoma and Untreated Brain Metastases: A Case Report
    Yeh, Justin
    Marks, Jennifer A.
    Alzeer, Ali H.
    Sloan, Emily A.
    Varghese, Reshma
    Paudel, Nitika
    Reuss, Joshua E.
    Bergquist, Peter J.
    Liu, Stephen, V
    Kim, Chul
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (12):
  • [39] Sotorasib-induced liver and non-liver toxicity associated with sequential sotorasib following anti-PD(L)1 in KRASG12C mutant lung cancer
    Chour, A.
    Denis, J.
    Lafitte, C.
    Mascaux, C.
    Zysman, M.
    Lemaitre, A.
    Swalduz, A.
    Gounant, V.
    Cortot, A.
    Darrason, M.
    Cadranel, J.
    Auclin, E.
    Basse, C.
    Tissot, C.
    Decroisette, C.
    Bombaron, P.
    Giroux-Leprieur, E.
    Falchero, L.
    Lebosse, F.
    Duruisseaux, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S49 - S50
  • [40] Gene expression correlates of adagrasib response in KRASG12C mutated non-small cell lung cancer (NSCLC)
    Kim, Eejung
    Tong, Xinyuan
    Patel, Ayushi
    Liu, Shengwu
    Dilly, Julien
    Hover, Laura
    Mukhopadhyay, Suman
    Sherman, Fiona
    Christensen, James G.
    Olson, Peter
    Aguirre, Andrew
    Wong, Kwok
    Ji, Hongbin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345